Department of Cancer Dermatology, INSERM U892, University Hospital Hôtel-Dieu, Place Alexis Ricordeau, Nantes, France.
Dermatology. 2010;220(4):370-5. doi: 10.1159/000305354. Epub 2010 May 13.
The mechanisms of action of bexarotene are not well understood.
A retrospective study on patients with cutaneous T-cell lymphoma (CTCL) treated with bexarotene was performed to see if bexarotene could act on the dominant T-cell clones. Thirty-five patients were included. Twenty-three were treated with bexarotene for more than 3 months (300 mg/m(2)). In 7 patients, phototherapy was given with bexarotene.
Dominant T-cell clones were observed in 11 patients in peripheral blood and in 19 patients in skin. Our results demonstrate no significant evolution of T-cell clones either in skin or peripheral blood. Furthermore, the detection of T-cell clones in peripheral blood before starting bexarotene was significantly associated with the progression of the disease. UV therapy given with bexarotene significantly improved therapeutic response without any correlation with T-cell clones.
This is the first study on the evolution of the T-cell clone in blood and skin in CTCL patients during bexarotene therapy.
贝沙罗汀的作用机制尚不清楚。
对接受贝沙罗汀治疗的皮肤 T 细胞淋巴瘤（CTCL）患者进行回顾性研究，以观察贝沙罗汀是否能作用于优势 T 细胞克隆。共纳入 35 例患者。23 例患者接受贝沙罗汀治疗超过 3 个月（300mg/m2）。7 例患者联合光疗。
在 11 例患者的外周血和 19 例患者的皮肤中观察到优势 T 细胞克隆。我们的结果表明，无论是在皮肤还是外周血中，T 细胞克隆均无明显演变。此外，在开始贝沙罗汀治疗前外周血中 T 细胞克隆的检测与疾病进展显著相关。与 T 细胞克隆无关，联合贝沙罗汀的 UV 治疗显著改善了治疗反应。
这是第一项关于 CTCL 患者在接受贝沙罗汀治疗期间血液和皮肤中 T 细胞克隆演变的研究。
